<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522648</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT</org_study_id>
    <nct_id>NCT04522648</nct_id>
  </id_info>
  <brief_title>Prospective Surveillance for Breast Cancer-Related Lymphedema</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Prospective Surveillance for Breast Cancer-Related Lymphedema: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial will test the effect of a prospective surveillance program for early&#xD;
      detection and subclinical management of breast cancer-related lymphedema on the prevalence of&#xD;
      chronic lymphedema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design and setting: This trial is a multi-center single-blind trial involving five hospitals&#xD;
      in Denmark.&#xD;
&#xD;
      Procedure: All women booked for surgery for breast cancer at one of the study sites will be&#xD;
      invited to participate. Women, who provide written informed consent, will have BIS&#xD;
      measurements, and perform self-measurements of arm circumference. Further, participants will&#xD;
      complete a sociodemographic questionnaire which will be used to ensure recruitment of a&#xD;
      representable sample. This data will be collected at the hospital of surgery at&#xD;
      pre-treatment. After surgery, women who had &gt;6 lymph nodes removed and have planned radiation&#xD;
      therapy will be randomized 1:1 into intervention or control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of chronic lymphedema</measure>
    <time_frame>At 24 months post-surgery</time_frame>
    <description>A binary outcome (y/n) defined as BIS ≥10 from pre-surgery or outside normal range ±10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-treatment</measure>
    <time_frame>INT group: will be collected throughtout the study period. CON group: at 6, 12, 18 and 24 months post-surgery</time_frame>
    <description>INT group: The time (weeks) from surgery to first elevated L-DEX score which triggers immediate treatment along with time (weeks) to resolution of BCRL from diagnosis. For CON: time from surgery to BCRL diagnosis, time from diagnosis to BCRL treatment, and time from initiation to termination of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>pre-treatment, 6, 12, 18 and 24 months post-surgery</time_frame>
    <description>This will be measured by the EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm function</measure>
    <time_frame>pre-treatment, 6, 12, 18 and 24 months post-surgery</time_frame>
    <description>This will be measured by the QuickDASH questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention (INT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INT participants will be asked to perform self-measurements of arm circumference at five points along the arm at home every three months. Additional measurements can be performed if the participants experience signs of BCRL. Participants will report the self-measurements in cm and mm in an online questionnaire, or over the phone to a physiotherapist navigator, along with reporting sign and symptoms of BCRL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (CON)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The CON group will follow the usual post-operative care. CON participants will be prompted every 6 months by an online questionnaire to report if they have been diagnosed with BCRL and if so, month of initiation of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective surveillance</intervention_name>
    <description>A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.</description>
    <arm_group_label>Intervention (INT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female;&#xD;
&#xD;
          -  ≥18 years;&#xD;
&#xD;
          -  surgery for breast cancer (unilateral and bilateral) including ALDN with &gt;6 lymph&#xD;
             nodes removed;&#xD;
&#xD;
          -  can effectively communicate verbally in Danish;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  surgery for breast cancer with SLNB or &lt; 6 nodes removed;&#xD;
&#xD;
          -  pre-existing lymphedema (primary or secondary);&#xD;
&#xD;
          -  previous treatment for breast cancer;&#xD;
&#xD;
          -  pace maker;&#xD;
&#xD;
          -  conditions known to cause swelling (pregnancy, congestive heart failure, chronic/acute&#xD;
             renal disease, cor pulmonale, nephrotic syndrome, nephrosis, liver failure or&#xD;
             cirrhosis, pulmonary edema, and thrombophlebitis or deep vein thrombosis in the arms).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bolette S Rafn, PhD</last_name>
    <phone>+45 22913873</phone>
    <email>bolette.skjoedt.rafn@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoffer Johansen, Professor</last_name>
    <phone>+45 26169014</phone>
    <email>christoffer.johansen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bolette Rafn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bolette Rafn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bolette Rafn</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Bolette Rafn</investigator_full_name>
    <investigator_title>Postdoc</investigator_title>
  </responsible_party>
  <keyword>lymphedema</keyword>
  <keyword>Prospective surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

